Jobs IRLDecoding DemocracyA Warmer WorldI've Always Wondered ...

Loading...

0:00
0% played
Stories Tagged as

Pharmaceuticals

The Price of Profits

Pharma: an industry shaped by shareholder value

by Dan Bobkoff
Jun 15, 2016
Big drug companies today have remade their business models.
Big Pharma has remade their business models over time to maximize shareholder value. 
Joe Raedle/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Cigna deal calls for rebates if drugs don't perform

by Dan Gorenstein
May 11, 2016
It's the seventh such deal for the insurance giant, which is putting pressure on drug makers in an effort to keep costs down.
Rosemary Petty, a Publix Supermarket pharmacy technician, counts out a prescription August 7, 2007 in Miami, Florida. 
Joe Raedle/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Turns out hedge funds have an incentive to control drug prices

by Dan Gorenstein
Apr 25, 2016
Hedge funds are joining groups who want to lower prescription prices for consumers.
Big Pharma doesn't like the patent review board. But organizations that want to lower prescription prices for consumers love it, and they're being joined in their fight by people who aren't usually seen as champions of consumer rights — hedge fund managers.
Photo by Joe Raedle/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Slashing incentives to prescribe expensive drugs

by Dan Gorenstein
Mar 9, 2016
A new proposal to cut Medicare drug spending costs has left doctors fuming.
Roxana Selagea, a Publix Supermarket pharmacy manager on August 7, 2007 in Miami, Florida. 
Joe Raedle/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

A push for more transparency in drug research costs

by Dan Gorenstein
Feb 16, 2016
The industry worries it's a step toward price controls.
Drug companies are not only in the spotlight for price setting, but now they may be required to be transparent about R&D spending. 
Kiran Foster/Flickr
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Survey shows drug price hikes widespread in industry

by Ashley Milne-Tyte
Feb 4, 2016
It's not just a few bad players, as Congressional hearing puts drug costs in focus.
PHILIPPE HUGUEN/AFP/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Congress turns its attention to high drug prices

by Dan Gorenstein
Jan 21, 2016
This may actually lower drug costs.
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

For public good, not for profit.

Donate

Vitamins and supplements are a dangerous business

by Kai Ryssdal and Mukta Mohan
Jan 19, 2016
'Supplements and Safety' reveals the hidden dangers of a multi-billion dollar industry
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Why rare-disease treatments can be big business

by Annie Baxter
Jan 11, 2016
Combined, Shire and Baxalta expect 65 percent of total revenue to come from rare disease treatments.
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
Final Note

Martin Shkreli arrested, but where's the Wu-Tang album?

by Kai Ryssdal
Dec 17, 2015
America's least favorite CEO was arrested Thursday.
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE